N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as Edg receptor agonists
View Patent ↗The present invention encompasses compounds of Formula (I) as well as the pharmaceutically acceptable salts and hydrates thereof. The compounds are useful for treating immune mediated diseases and conditions, such as bone marrow, organ and tissue transplant rejection. Pharmaceutical compositions and methods of use are included.
1. A compound of Formula I
or a pharmaceutically acceptable salt or hydrate thereof, wherein:
Ar is phenyl;
A is —CO 2 H;
n is 2, 3 or 4;
each R 1 and R 2 is independently selected from the group consisting of: hydrogen, halo, hydroxy, —CO 2 H, C 1-6 alkyl and phenyl, said C 1-6 alkyl and phenyl optionally substituted with 1-3 halo groups;
R 3 is selected from the group consisting of: hydrogen and C 1-4 alkyl, optionally substituted with 1-3 hydroxy or halo groups;
each R 4 is independently selected from the group consisting of: hydroxy, halo, —CO 2 H, C 1-4 alkyl, —S(O) k C 1-3 alkyl, wherein k is 0, 1 or 2, C 1-3 alkoxy, C 3-6 cycloalkoxy, aryl and aralkoxy, the alkyl portions of said C 1-4 alkyl, —S(O) k C 1-3 alkyl, C 1-3 alkoxy and C 3-6 cycloalkoxy optionally substituted with 1-3 halo groups;
C is HET, wherein HET is thienyl;
B is selected from the group consisting of: C 1-6 alkyl, C 1-5 alkoxy, —(C═O)—C 1-5 alkyl, —(C═O)—O—C 1-4 alkyl, —(C═O)—N(R 6 )(R 7 )—C 1-4 alkyl,
phenyl and HET; and
R 6 and R 7 are independently selected from the group consisting of: hydrogen, C 1-9 alkyl and —(CH 2 ) p -phenyl, wherein p is 1 to 5 and phenyl is optionally substituted with 1-3 substituents independently selected from the group consisting of: C 1-3 alkyl and C 1-3 alkoxy, each optionally substituted with 1-3 halo groups.
2. The compound according to claim 1 wherein n is 2.
3. The compound according to claim 1 wherein n is 3.
4. The compound according to claim 2 wherein each R 1 and R 2 is independently selected from the group consisting of: hydrogen, —CO 2 H, hydroxy, halo, C 1-3 alkyl and phenyl.
5. The compound according to claim 1 wherein R 3 is hydrogen or methyl.
6. The compound according to claim 1 wherein each R 4 is independently selected from the group consisting of: halo, hydroxy, C 1-3 alkyl, C 1-3 alkoxy, C 1-3 alkylthio, phenyl, benzyloxy and cyclopropyloxy.
7. The compound according to claim 1 wherein B—C is
8. The compound according to claim 1 wherein Ar is phenyl and the group —B—C is attached to the phenyl ring at the 3- or 4-position.
9. A compound of Formula II
or a pharmaceutically acceptable salt or hydrate thereof, wherein
the group —B—C is attached to the phenyl ring at the 3- or 4-position;
n is 2, 3 or 4;
each R 1 and R 2 is independently selected from the group consisting of: hydrogen, —CO 2 H, hydroxy, halo, C 1-3 alkyl and phenyl, said C 1-3 alkyl and phenyl optionally substituted with 1-3 halo group;
A is —CO 2 H;
R 3 is hydrogen or methyl;
each R 4 is independently selected from the group consisting of: halo, hydroxy, C 1-3 alkyl, C 1-3 alkoxy, C 1-3 alkylthio, phenyl, benzyloxy and cyclopropyloxy; and
B—C is
10. A compound selected from the group consisting of:
or a pharmaceutically acceptable salt of any of the foregoing compounds.